Pharmacokinetics, Safety, and Bioequivalence of 2 Lopinavir/Ritonavir (200/50 mg) Tablets in Healthy Chinese Volunteers: Effect of Food on Absorption
Clinical Pharmacology in Drug Development · 2023-06 · 12 (6) · 602-610
DOI: 10.1002/cpdd.1229 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Clinical Pharmacology in Drug Development, online erschienen am 15.02.2023. Verfasst von Wei Zhang und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Pharmacology, The Second Hospital of Anhui Medical University, Hefei, China. Hauptthemen laut MEDLINE: Lopinavir, Ritonavir. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 24 Literaturangaben. Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
Lopinavir/ritonavir is an important protease inhibitor for treating HIV‐1 infection in patients aged >2 years in combination with other antiretrovirals. The antiviral activity of lopinavir/ritonavir in vivo is mainly derived from lopinavir, while ritonavir improves the bioavailability of lopinavir. This study compared the bioequivalence and safety of 2 lopinavir/ritonavir (200/50 mg) formulations under fasted and fed conditions in healthy Chinese volunteers and compared the pharmacokinetic parameters of lopinavir and ritonavir. A randomized, open‐label, single‐dose, 4‐period, crossover bioequivalence was conducted in 72 subjects under fasted and fed conditions. Lopinavir and ritonavir plasma concentrations were analyzed using validated liquid chromatography with tandem mass spectrometry. Noncompartmental analysis was used to evaluate pharmacokinetic parameters. The 90% confidence intervals of test/reference geometric mean ratio for lopinavir and ritonavir area under the plasma concentration–time curve and maximum drug concentration meets the bioequivalence criteria based on the average bioequivalence method. A high‐fat meal delayed the time to the maximum concentration of lopinavir and ritonavir. Therefore, these formulations were bioequivalent in healthy Chinese volunteers under fasting and fed conditions. Moreover, adverse events were more frequent in the fed state, but all were mild.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Clinical Pharmacology, The Second Hospital of Anhui Medical University, Hefei, China.
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Zhang, W., Lin, L., Fu, W., Bao, D., Zhang, Q., Liu, Y., Zheng, L., & Hu, W. (2023). Pharmacokinetics, Safety, and Bioequivalence of 2 Lopinavir/Ritonavir (200/50 mg) Tablets in Healthy Chinese Volunteers: Effect of Food on Absorption. Clinical Pharmacology in Drug Development, 12(6), 602-610. https://doi.org/10.1002/cpdd.1229
Vancouver
Zhang W, Lin L, Fu W, Bao D, Zhang Q, Liu Y, et al. Pharmacokinetics, Safety, and Bioequivalence of 2 Lopinavir/Ritonavir (200/50 mg) Tablets in Healthy Chinese Volunteers: Effect of Food on Absorption. Clinical Pharmacology in Drug Development. 2023;12(6):602-610. doi:10.1002/cpdd.1229
BibTeX
@article{Zhang2023,
author = {Zhang, Wei and Lin, Lili and Fu, Wanjin and Bao, Dandan and Zhang, Qian and Liu, Yueyue and Zheng, Liang and Hu, Wei},
title = {Pharmacokinetics, Safety, and Bioequivalence of 2 Lopinavir/Ritonavir (200/50 mg) Tablets in Healthy Chinese Volunteers: Effect of Food on Absorption},
journal = {Clinical Pharmacology in Drug Development},
year = {2023},
volume = {12},
number = {6},
pages = {602--610},
doi = {10.1002/cpdd.1229}
}
EUVIMED